PMO team
- Feb 10, 2022
- 1 min read

Discussion with the Medical Products Agency regarding the risk RA population

We have developed a Regulatory briefing book in RTCure. This has informed our regulatory discussions, identifying key issues such as the identification of unmet need, well-defined criteria to identifying patients at risk, and care pathway analysis with information on costs of early intervention vs potential savings to the society would be required. This document was the basis of initial discussion with the Swedish Medical Products Agency. Read it here!

RTCure Briefing Document - SA Meeting MPA

.pdf

Download PDF • 1.20MB

Recent Posts

See All

Can the immune system be reset in transplantation and autoimmunity?

Can the immune system be reset in transplantation and autoimmunity? A series of 4 reviews from the RTCure consortium is out and tells you all you wanted to know about curing autoimmunity but were afra

Two PRP's share about their involvement with RTCure

Tom Esterine and Ruth Williams are two Expert Patients at King’s College London, who work with Heidi Lempp in the Centre for Rheumatic Disease. With a lot of enthusiasm, they share their insight in wo

PRP Newsletter - May 2020

Following this link you can find the EULAR Patient Research Partners newsletter of May 2020. This newsletter contains an invitation to the virtual EULAR 2020 E-Congress, links to interesting articles